David Cheng, MD
Emergency Medical Services · Flushing, NYNPI 1124075577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Organogenesis Inc. at 35.7% of the total. Reporting peaked in 2019 at $427 and has fallen 94.7% since, to $23 in 2025.
Across 35 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$247
- Aroa Biosurgery Incorporated$92
- Tactile Systems Technology Inc$65
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$55
- GSK$35
- Mylan Specialty L.p.$26
- plus $172 from 10 others
What the payments were for
- Food & beverage$692100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 8 | $247 |
| Aroa Biosurgery Incorporated | 8 | $92 |
| Tactile Systems Technology Inc | 2 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| GSK | 2 | $35 |
| Mylan Specialty L.p. | 1 | $26 |
| Smith+Nephew | 1 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| AbbVie | 1 | $13 |
| Novo Nordisk | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$692 in reported general payments places this provider in the 85th percentile of 74 emergency medical services providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $448 |
| Fluticasone Propionate | 21 | $254 |
| Omeprazole | 22 | $240 |
| Levothyroxine Sodium | 15 | $209 |
| Methylprednisolone | 31 | $198 |
| Rosuvastatin Calcium | 18 | $187 |
| Doxycycline Hyclate | 15 | $112 |
| Famotidine | 21 | $72 |
| Azithromycin | 18 | $65 |
| Buspirone Hcl | 13 | $26 |
| Meloxicam | 11 | $5 |
Paid to pharmacies, not to this prescriber.
Other emergency medical services in Flushing
- Nathan ZariderFlushing$278
- Ronald SomogyiKenmore$14K
- Yvette CalderonBronx$11K
- Ugo EzenkweleBrooklyn$4K
- Daniel LopezCortlandt Manor$4K
- Kenneth HirschPort Jefferson$2K
- Steven BradleyLewiston$2K
- Reine JamesWest Islip$1K
- Mark WilkowskiCheektowaga$1K
- Corey WeinerBrooklyn$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.